1. Optimizing the management of renal anemia: challenges and new opportunities 
Francesco Locatelli, Lucia Del Vecchio 
Kidney International 
Volume 74, Pages S33-S37 (December 2008)
DOI: /ki
Copyright © 2008 International Society of Nephrology Terms and Conditions

2. Figure 1
Hb concentrations during correction phase with CERA, rHuEPO, and darbepoetin alpha in EPO-naive CKD patients not on dialysis. The observed raise in Hb concentration is smothering with CERA than with other ESAs. Data are obtained from reference Macdougall et al.21 and from reference Locatelli et al.13 CERA, continuous erythropoiesis receptor activator; CKD, chronic kidney disease; Hb, hemoglobin; rHuEPO, recombinant human erythropoietin.
Kidney International  , S33-S37DOI: ( /ki )
Copyright © 2008 International Society of Nephrology Terms and Conditions

3. Figure 2
Hb decrease rate after drug withdrawal in patients exceeding Hb levels of 14g per 100ml with different ESAs. The rate of decrease is influenced by erythrocyte- and not by drug half-life. Data are obtained from reference Locatelli et al.13 and reference Heifets et al.49 CERA, continuous erythropoiesis receptor activator; ESAs, Erythropoiesis-stimulating agents; Hb, hemoglobin.
Kidney International  , S33-S37DOI: ( /ki )
Copyright © 2008 International Society of Nephrology Terms and Conditions